Results 51 to 60 of about 33,240 (248)

Somatic Evolution of a Germline Antibody Expands its Breadth to Neutralize Early SARS‐CoV‐2 Omicron Variants

Advanced Science, EarlyView.
Engineering of the 148‐germline (148‐GL) antibody reveals a roadmap for overcoming SARS‐CoV‐2 viral escape. By introducing four specific somatic hypermutations, the resulting 148‐M4 variant restores potent neutralization against Omicron BA.1 and BA.4/5.
Huibin Lv, Ziqi Feng, Qi Wen Teo, Chunke Chen, Akshita B. Gopal, Danbi Choi, Timothy J. C. Tan, Yun Sang Tang, Lewis Siu, Armita Nourmohammad, Roberto Bruzzone, Ian A. Wilson, Meng Yuan, Nicholas C. Wu, Chris K. P. Mok   +14 more
wiley   +1 more source

Antiretroviral agents against human immunodeficiency virus

DST, 2022
Introduction: Since its discovery in the 1980s, the human immunodeficiency virus (HIV) has been the target of many studies. Nowadays, estimates show that 36.7 million people are infected with HIV worldwide.
Ingrid Barcelos de Oliveira, Claudio Cesar Cirne Santos, Izabel Christina Nunes de Palmer Paixão, Caroline de Souza Barros, Rosa Teixeira Pinho   +4 more
doaj  

Further Characterization of the Bifunctional HIV Entry Inhibitor sCD4-FIT45

Molecular Therapy: Nucleic Acids, 2017
HIV entry into target cells is a highly sequential and time-sensitive process. In recent years, potent HIV Env-targeting antibodies, such as VRC01, have been identified.
Alexander Falkenhagen, Sadhna Joshi
doaj   +1 more source

Membrane-anchored HIV-1 N-heptad repeat peptides are highly potent cell fusion inhibitors via an altered mode of action. [PDF]

PLoS Pathogens, 2009
Peptide inhibitors derived from HIV-gp41 envelope protein play a pivotal role in deciphering the molecular mechanism of HIV-cell fusion. According to accepted models, N-heptad repeat (NHR) peptides can bind two targets in an intermediate fusion ...
Yael Wexler-Cohen, Yechiel Shai
doaj   +1 more source

Dual Blockade of LILRB1 and LILRB2 Enhances Antiviral Immune Responses in SIV Infection

Advanced Science, EarlyView.
Dual LILRB1/B2 blockade with mac20G10 reshapes myeloid activation during acute SIV infection by targeting LILRB1 and LILRB2 on myeloid cells. This treatment enhances CD80 expression on selected myeloid subsets and increases plasma IFN‐λ, IL‐8, and IL‐1RA.
Florian Meurisse, Sixtine Coindre, Anne Wijkhuisen, Romain Marlin, Laure Fournier Le Ray, Juliette Pons, Melyssa Yaugel‐Novoa, Véronique Avettand‐Fenoel, Laurent Abi‐Rached, Anne‐Sophie Gallouet, Francis Relouzat, Mael Gourves, Asier Saez‐Cirion, Hisashi Arase, Gerard Zurawski, Sandra Zurawski, Nathalie Dereuddre‐Bosquet, Roger Le Grand, Stéphanie Simon, Olivier Lambotte, Benoit Favier   +20 more
wiley   +1 more source

Targeted Degradation of Picornaviral 3C Protease via PROTACs Confers High Barrier to Viral Resistance and Broad‐Spectrum Antiviral Activity

Advanced Science, EarlyView.
This study reports D34 as the first PROTAC degrader that targets the 3C protease of picornaviruses. D34 effectively degrades EV71 3C protease via the ubiquitin‐proteasome pathway. More importantly, D34 exhibits a high resistance barrier and shows broad‐spectrum antiviral activity against multiple picornaviruses, highlighting its potential as a novel ...
Weilong Deng, Junyu Chen, Yingyue Pang, Yuanyuan Zhang, Siqian Chen, Guoliang You, Xiaoman Tian, Zhongxin Xu, Jing Wang, Luqing Shang   +9 more
wiley   +1 more source

Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding. [PDF]

PLoS Pathogens, 2009
Both equilibrium and nonequilibrium factors influence the efficacy of pharmaceutical agents that target intermediate states of biochemical reactions. We explored the intermediate state inhibition of gp41, part of the HIV-1 envelope glycoprotein complex ...
Kristen M Kahle, H Kirby Steger, Michael J Root   +2 more
doaj   +1 more source

Programmable Nanobody‐Targeting Chimeras Enable Intracellular Viral Protein Degradation

Advanced Science, EarlyView.
Nab‐TAC enables targeted degradation of HBV surface antigen (HBsAg) in vivo. By fusing nanobody‐based recognition domains with programmable proteasome‐recruiting degradation signals, Nab‐TAC reduces HBsAg levels in a hydrodynamic HBV mouse model. ABSTRACT Chronic hepatitis B virus (HBV) infection remains a major global health challenge, largely because
Max Yu‐Chen Pan, Ting‐Hui Lee, Tzu‐Ning Peng, Eva Yi‐Hsuan Wu, Yu‐Ting Chiu, Chih‐Chien Chiu, Hong Vinh Nguyen, Yuan‐Shao Pao, Ming‐Hong Chao, Richard Kuan‐Lin Lee, Han‐Chung Wu, Lily Hui‐Ching Wang   +11 more
wiley   +1 more source

Susceptibility of HIV-1 subtypes B', CRF07_BC and CRF01_AE that are predominantly circulating in China to HIV-1 entry inhibitors. [PDF]

PLoS ONE, 2011
The B', CRF07_BC and CRF01_AE are the predominant HIV-1 subtypes in China. It is essential to determine their baseline susceptibility to HIV entry inhibitors before these drugs are used in China.The baseline susceptibility of 14 representative HIV-1 ...
Xiaoling Yu, Lin Yuan, Yang Huang, Weisi Xu, Zhiming Fang, Shuwen Liu, Yiming Shao, Shibo Jiang, Liying Ma   +8 more
doaj   +1 more source

TRIM28‐Derived Peptide Exerts Anti‐Tumor Roles by Stabilizing Tumor Suppressive BRD7 Protein in Multiple Cancers

Advanced Science, EarlyView.
An α‐helical peptide, TAB12, designed to mimic the TRIM28 binding interface, competitively disrupts the TRIM28‐BRD7 interaction, thereby blocking ubiquitin‐mediated degradation of the tumor suppressor BRD7. This stabilization unleashes potent anti‐tumor effects across multiple tumor types with a favorable safety profile, offering a feasible strategy ...
Qingqing Wei, Changning Xue, Mengna Li, Jianxia Wei, Lemei Zheng, Shipeng Chen, Yijie Wang, Yumei Duan, Yanwei Luo, Wei Xiong, Ming Zhou   +10 more
wiley   +1 more source